Tulane Eosinophilic Disorder Center
Our Aim: Learn,Teach, Researchand Cure
Home Team Research Clinical Contact Donation
Tulane Center for Eosinophilia Disorders under the leadership of Dr. Anil Mishra, PhD, is a first center in the southern region of USA. The center will provide an opportunity to the researchers, patients and their families to understand the disease and consult for the better treatment of the eosinophil associated disorders. The center will also provide an opportunity to the basic research scientist to directly translate their experimental findings to the human disease with the help of clinicians. The center will be involved in basic, clinical and translational studies to determine the mechanistic aspects of eosinophilic disorders in the lung, skin and multiple gastrointestinal segments. The center's aim is to develop a diagnostic and therapeutic interventions for eosinophil associated multiple diseases. Eosinophilic disorders occur when eosinophils, white blood cells with a bilobed nucleus with multiple toxic granules white blood cell, are found in above-normal amounts in various parts of the body. At healthy state the eosinophil reside in the gastrointestinal tract; however, during allergic (food or aeroallergen) responses, a large number of eosinophils are generated from their precursors in response to the stimulus and move into the sites (responsive organ of the body) and release a variety of toxins that can cause chronic inflammation, resulting in tissue damage and repair.
Eosinophils have a critical role in promoting asthma, dermatitis, multiple gastrointestinal disorders and tissue remodeling (fibrosis)
We and other investigators found that eosinophils have a major role in promoting asthma, dermatitis and a number of gastrointestinal symptoms. Because of the growing knowledge and a better diagnostic technology, we have now better understanding of a number of allergic diseases. We are currently studying multiple compounds that might block eosinophil production and their recruitment into the tissues. Our research work indicated that in future we could provide the best treatment for eosinophil-associated multiple medical disorders such as asthma, eosinophilic dermatitis, eosinophil associated gastrointestinal disorders and tissue remodeling (fibrosis).
Basic and Clinical Studies at Our Center
Dr. Mishra's general research is aimed at deciphering mechanisms of inflammation, primarily based on discoveries concerning innate immunity. In particular, gene-environment interactions in the elicitation of inflammatory states in the respiratory and gastrointestinal tracts are under investigation. Environmental triggers (such as aeroallergens and food allergens) are studied in the context of specific genetic variants (e.g. IL-15 and IL-18 signaling) using population studies (cross sectional and longitudinal prospective cohorts) and mechanism-driven studies. The biological properties of innate inflammatory cells (eosinophil, mast cells, NKT cells, epithelial cells) and the cytokines (especially chemokines) that mediate their function are under investigation. The contribution of these basic processes to diverse human inflammatory conditions (e.g. asthma, eosinophil associated gastrointestinal disorders) is pursued by translational studies often involving unique clinical resources (e.g. patient samples and databanks) and clinical intervention studies (e.g. anti-cytokine therapeutics).
Anil Mishra, PhD, Endowed Schlieder Chair and Professor of Medicine, Pulmonary Diseases, Director, Tulane Eosinophilic Disorder Center, Tulane Medical Center, New Orleans, LA 70112
Focus area of our research
Eosinophilic gastrointestinal Disorders:
Eosinophilic esophagitis, characterized by elevated levels of eosinophil in the esophagus.
Eosinophilic gastritis, characterized by elevated eosinophil in the stomach.
Eosinophilic enteritis, characterized by elevated eosinophil in the intestine.
Eosinophilic colitis, characterized by excessive eosinophil in the colon.
Clinical Collaborators (s)
1. Uwe Blecker, MD (Pediatric Gastroentrology and Hepatology, Tulane Medical Center, New Orleans, LA)
2. Rober Bulat, MD (Adult Gastroentrology and Hepatology Section, Tulane Medical center, New Orleans, LA)
Asthma, is a chronic inflammatory disease of the airways caused by a combination of genetic and environmental factors and characterized by airflow obstruction, and bronchospasm. Common symptoms include wheezing, coughing, chest tightness, and shortness of breath.
Clinical Collaborators. Dr. Nereida Parada, MD (Associate Professor, Pulmonary Medicine. Tulane Medical Center, New Orleans, LA)
Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. This can be a reactive, benign, or pathological state.
Clinical Collaborators. Dr. Joseph Lasky, MD (Professor and Director, Pulmonary Medicine. Tulane Medical Center, New Orleans, LA)
Fibrosis can occur in many tissues within the body, typically as a result of inflammation or damage, and examples include:
-Pulmonary fibrosis (lungs) includes, Idiopathic pulmonary fibrosis.
-Nephrogenic systemic fibrosis (skin)
-Crohn's Disease (intestine)
Dr. Luis Balart, MD (Professor and Director, Adult Gastroentrology and Hepatology Section, Tulane Medical center, New Orleans, LA)
Jane M. El-Dhar, MD (Professor of Clinical Pediatrics and Clinical Professor of Medicine, Head, Section of Pediatric Allergy/Immunology/Rheumatology
Dr. Laurianne Wild, MD (Professor and Director, Clinical Immunology, Tulane Medical Center, New Orleans, LA
Dr. John Affornti, MD, Professor of Medicine Interim Chief Division of Gastroenterology & Hepatology
Off Site Collaborative Partner and Consultants
1. Paul E. Hyman, MD, Professor Pediatrics, Division Head, Children's Hospital, New Orleans, LA 70118. Email: firstname.lastname@example.org, Ph 504-896-9334, FAX 504-894-5567
2. Sandeep K. Gupta, M.D., Professor of Clinical Pediatrics & Clinical Medicine Director, Pediatric Over Weight Education and Research Program, Riley Hospital for Children, Indianapolis, IN. email: email@example.com
3. Manoj R. Warrier, MD, Allergy, Asthma & Sinus Care Center 12818 Tesson Ferry Road, Suite #103, St. Louis, MO 63128; Phone: 314.849.8700; Fax: 314.849.8737; email. firstname.lastname@example.org
4. Hamid A. Boulares, PhD, Professor of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center; New Orleans, LA 70112.Phone: 504-210-2233 Email: email@example.com
Future clinical trials
1. rIL-15 therapy for lung and esophageal fibrosis.
2. rIL-15 therapy for airway restrictions (airway hyperactivity).
3. Anti-CD1d and anti-Vα24Jα18 therapy to target iNKT cells for the treatment of eosinophilic esophagitis.
Patients and Family
Patients and families are encouraged to contact our center for the information's needed to understand disease pathogenesis or treatment procedure for eosinophil related disorders.
Tulane Eosinophilic Disorder Center
Ph # 505- 988 - 3840
FAX # 504- 988 - 2144
Principal Investigator: Anil Mishra, PhD,
Clinical Coordinator: Christine Glynn, RN
Funds needed for diagnostic and therapeutic Interventions.
Currently, we have very limited support from NIH and our research is very limited. We are in a need of funds to support of research program to find a permanent cure for eosinophil related lung skin and gastrointestinal disorders. We appeal to the common people and private funding agencies to provide the donations for our research programs.
Our research highlights.
1. Eosinophils are the resident cell that home prenatally in gastrointestinal tract. J. Clin. Invest. 1999
2. Developed a murine model of asthma associated eosinophilic esophagitis. J. Clin. Invest. 2001
3. Esophageal remodeling develops as a consequence of tissue specific IL-5 induced eosinophilia. Gastroenterology. 2008
4. Interleukin-15 Expression Is Increased in Human eosinophilic esophagitis and Mediates Pathogenesis in Mice. Gastroenterology. 2010
5. Esophageal functional impairments in experimental eosinophilic esophagitis. AJP-Gastroenterology & Liver Physiol 2009
6. Invariant natural killer T cells neutralization is a possible novel therapy for human eosinophilic esophagitis. Clinical and Translational Immunology, 2014
7. Significance of mouse models in dissecting the mechanism of human eosinophilic gastrointestinal diseases (EGID). J Gastroenterology and Hepatology 2013
8. Resistin-like molecule (Relm)-a induction in eosinophilic esophagitis promotes esophageal epithelial cell hyperplasia. AJP-Gastroentrology. 2014
9. Involvement of Interleukin-18 in the pathogenesis of human eosinophilic esophagitis. Clinical Immunology, 2015
10. Possible Noninvasive Biomarker of Eosinophilic Esophagitis: Clinical and Experimental Evidence.Case Reports in Gastroenterology. 2016
11. Regulatory effects of Interleukin (IL)-15 on allergen-induced airway obstruction.J. Allergy and Clinical Immunology. 2017
1430 Tulane Ave, New Orleans, LA 70112 504-988-2250 firstname.lastname@example.org